Person:
TOPÇU, ATAKAN

Profile Picture
Status
Kurumdan Ayrılmıştır
Organizational Units
OrgUnit Logo
Organizational Unit
Job Title
First Name
ATAKAN
Last Name
TOPÇU
Name
Email Address
Birth Date

Filters

2021 - 20222
Reset filters

Settings

Author: BEŞİROĞLU, MEHMET × Rights: info:eu-repo/semantics/openAccess ×

Search Results

Now showing 1 - 2 of 2
  • Thumbnail Image
    PublicationOpen Access
    Anxiety levels of breast cancer patients in Turkey during the COVID-19 pandemic
    (2021-07-01T00:00:00Z) YASİN, Ayşe İrem; TOPÇU, Atakan; SHBAIR, ABDALLAH T.M.; SUCUOĞLU İŞLEYEN, ZEHRA; ÖZTÜRK, AHMET; BEŞİROĞLU, MEHMET; TÜRK, HACI MEHMET; YASİN, AYŞE İREM; TOPÇU, ATAKAN; SHBAIR, ABDALLAH T.M.; SUCUOĞLU İŞLEYEN, ZEHRA; ÖZTÜRK, AHMET; BEŞİROĞLU, MEHMET; TÜRK, HACI MEHMET
    Aim: To assess the anxiety levels of breast cancer patients during the COVID-19 pandemic. Materials & methods: A total of 298 patients completed the State-Trait Anxiety Inventory (STAI-S and STAI-T) and the Visual Analogue Scale for Anxiety (VAS) and VAS for Anxiety in COVID-19 (VAS-CoV). Results: 144 patients were in the high anxiety category for STAI-S, and 202 patients were in the high anxiety category for STAI-T. STAI-T score was significantly high in the metastatic group (p = 0.017). VAS-CoV score in the hormonotherapy group was significantly higher than in the no-treatment group (p = 0.023). There was a positive correlation between VAS-CoV and VAS levels (r = 0.708, p < 0.001), VAS-CoV and STAI-S and STAI-T scores (r = 0.402, p < 0.001; r = 0.185, p = 0.001, respectively), and a negative correlation between education years and STAI-T scores (r = -0.172, p = 0.003). Conclusion: The COVID-19 pandemic is related to high anxiety levels in breast cancer patients.
  • Thumbnail Image
    PublicationOpen Access
    The efficacy of BNT162b2 (Pfizer-BioNTech) and CoronaVac vaccines in patients with cancer
    (2022-05-01T00:00:00Z) ŞİMŞEK, MELİH; Yasin, Ayse; BEŞİROĞLU, MEHMET; TOPÇU, Atakan; SUCUOĞLU İŞLEYEN, ZEHRA; ŞEKER, Mesut; TÜRK, HACI MEHMET; ŞİMŞEK, MELİH; BEŞİROĞLU, MEHMET; TOPÇU, ATAKAN; SUCUOĞLU İŞLEYEN, ZEHRA; ŞEKER, MESUT; TÜRK, HACI MEHMET
    Although vaccination is efficacious and prevents infection in the general population, there is limited data about Coronavirus disease-19 (Covid-19) occurrence after vaccination in cancer patients. It was aimed to evaluate the efficacy of BNT162b2 (Pfizer-BioNTech) and CoronaVac vaccines against Covid-19 in patients with cancer. In this single-center, retrospective, cross-sectional, and descriptive study, the data of cancer patients referred to the medical oncology clinic of a university hospital were analyzed. The sample of the study consisted of cancer patients who had Covid-19 or were vaccinated against Covid-19. A total number of 2578 patients were included in the study. Of the patients, 2000 have never been infected with severe acute respiratory syndrome coronavirus and 578 patients have had a positive reverse-transcription polymerase chain reaction (RT-PCR) for Covid-19. It was found that 2094 patients (81.2%) were fully vaccinated, and 484 patients (18.8%) did not receive full-dose vaccination. A statistically significant difference in Covid-19 occurrence was found between the patients who had full-dose vaccination or not (p = 0.000). In in-group comparisons of full-dose vaccinated patients, while no difference was observed between two doses of BNT162b2 (Pfizer-BioNTech) and three doses of CoronaVac (p = 0.432), a statistically significant difference was observed between all other groups (p < 0.005). When the data of 578 patients who experienced Covid-19 was analyzed, a statistically significant difference was observed between the groups who were full-dose vaccinated and those who were not (p = 0.000). It is recommended that this vulnerable patient group should be prioritized in vaccination programs, and full-dose vaccination (at least two doses of vaccines) should be completed as soon as possible.